https://www.thebodypro.com/category/fda-approved-hiv-medications

FDA-Approved HIV Medications

The Latest

Promo Image
News

NNRTIs: The Next Generation Approaches (Part I)

Part I

Introduction Mechanisms of NNRTI Activity and HIV NNRTI Resistance NNRTI Resistance in NNRTI-Naive and NNRTI-Experienced Individuals NNRTI Mutations: Resistance and Cross-Resistance NRTI Mutations: The Potential Impact on NNRTIs NNR...

Promo Image

NNRTIs: The Next Generation Approaches (Part II)

Case Study: Patient JD

JD is a 46-year-old gay male. He first learned of his HIV status in 1994 after a former partner with whom he had been in a three-year relationship discovered that he was HIV infected.

JD felt well when he was first tested for...

Promo Image

Pipeline Update: Short Notes on New Anti-HIV Drugs in Development

The Phases of Drug Development Integrase Inhibitors Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Entry Inhibitors Protease Inhibitors Other Types of Anti-HIV Drugs

The Pha...

Promo Image
Conference Coverage

Brecanavir Shows Favorable Pharmacokinetics When Combined With Select PIs in Double-Boosted Regimens

Brecanavir (BCV, GW640385) is a new protease inhibitor (PI) in phase 2b clinical development by GlaxoSmithKline (Glaxo). It has shown powerful antiviral activity against both wild-type and highly drug-resistant HIV. One of its main attributes is that...

Promo Image

Acid-Reducing Agents Reduce Atazanavir Drug Levels but Not Lopinavir/Ritonavir Levels

Some protease inhibitors (PIs) -- notably atazanavir (ATV, Reyataz) -- have impaired absorption when coadministered with acid-reducing agents. In addition, antacids, H2 blockers and proton pump inhibitors are available over-the-counter and widely use...

Promo Image
News

Pharmacokinetic Data Show That Fosamprenavir + Atazanavir Combination Should Not Be Used

For HIV-infected patients with protease inhibitor (PI) resistance, there has been a lot of good news of late with the advent of PIs such as tipranavir (TPV, Aptivus) and TMC114. There also remains continued interest in the use of dual PIs for the tre...

Promo Image

Quadruple-NRTI Regimen No More Desirable Than Triple-NRTI Regimen in Treatment-Naive Patients, Study Finds

Adding tenofovir (TDF, Viread) to zidovudine/lamivudine/abacavir (AZT/3TC/ABC, Trizivir) does not appear to improve virologic outcome and does nothing to reduce treatment discontinuation rates in treatment-naive patients, according to a relatively sm...

Promo Image

Two NRTIs or Three? Makes No Difference When Taken With Efavirenz, ACTG 5095 Finds

When prescribing the potent antiretroviral efavirenz (EFV, Sustiva, Stocrin) as part of a first-line treatment regimen, there is no discernible difference between completing the regimen with two nucleoside reverse transcriptase inhibitors (NRTIs) or ...

Promo Image

New Protease Inhibitor Brecanavir Shown to Be Safe and Effective in Small Study

A key dilemma for both patients and doctors is when to use new drugs and new drug classes. A thorough understanding of the characteristics of new drugs helps in choosing what to use and what potential combinations would be appropriate, or when to wai...

Promo Image
Lipodystrophy/Body Fat

Protease Inhibitors Not Associated With Fat Gain; Some Antiretrovirals Can Cause Fat Loss, Study Says

Although some antiretroviral drugs are associated with weight loss in the extremities in HIV-positive men, weight gain is not associated with taking protease inhibitors, according to a study published in the Oct. 1 issue of the Journal of Acquired Im...